Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

AcuCort

0.59 SEK

-1.01 %

Less than 1K followers

ACUC

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-1.01 %
+1.90 %
-0.84 %
-35.20 %
-7.80 %
+0.41 %
-54.54 %
-83.34 %
-76.85 %

AcuCort is a pharmaceutical company. The company develops and commercializes pharmaceuticals based on well-established substances with a focus on user-friendliness and ease of administration. The company's leading product is an oral film for the acute treatment of allergic reactions and other conditions with high medical demand. Products are aimed at patients and caregivers globally. AcuCort was founded in 2006 and is headquartered in Lund, Sweden.

Read more
Market cap
138.56M SEK
Turnover
47.05K SEK
Revenue
680K
EBIT %
-2,557.35 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/2
2026

Annual report '25

All
Press releases
3rd party
ShowingAll content types
Press release12/2/2025, 9:16 AM

Investor Studios: Lär känna din VD: Jonas Jönmark, AcuCort

AcuCort
Regulatory press release11/28/2025, 9:00 AM

AcuCort AB: AcuCort appoints nomination committee

AcuCort
Regulatory press release11/28/2025, 9:00 AM

AcuCort AB: Valberedning i AcuCort utsedd

AcuCort

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/19/2025, 10:39 AM

Analyst Group: Aktieanalys på AcuCort - Intensifierade partnerdialoger

AcuCort
Press release11/17/2025, 9:10 AM

Analyst Group: Analyst Group kommenterar AcuCorts Q3-rapport

AcuCort
Regulatory press release11/14/2025, 7:30 AM

AcuCort AB: AcuCort publicerar delårsrapport för tredje kvartalet 2025

AcuCort
Regulatory press release10/14/2025, 11:00 AM

AcuCort AB: AcuCort stärker ledningsgruppen med rekryteringen av Anna Chérouvrier Hansson som Business Development Director

AcuCort
Regulatory press release10/14/2025, 11:00 AM

AcuCort AB: AcuCort strengthens its management team with the appointment of Anna Chérouvrier Hansson as Business Development Director

AcuCort
Press release9/25/2025, 1:00 PM

AcuCort AB: Nyhetsbrev: Intervju med Jan Poulsen, AcuCorts nya styrelseledamot

AcuCort
Regulatory press release9/25/2025, 7:28 AM

AcuCort AB: AcuCort beviljas förlängd SME-status av den europeiska läkemedelsmyndigheten (EMA)

AcuCort
Regulatory press release9/25/2025, 7:28 AM

AcuCort AB: AcuCort granted extended SME status by the European Medicines Agency (EMA)

AcuCort
Press release9/18/2025, 6:30 AM

AcuCort AB: AcuCorts VD presenterar på life science-konferens i Köpenhamn

AcuCort
Press release9/18/2025, 6:30 AM

AcuCort AB: AcuCort's CEO to present at Life Science Conference in Copenhagen

AcuCort
Press release8/28/2025, 12:15 PM

Analyst Group: Aktieanalys på AcuCort - Nya orders, LOI:er och regulatoriska framsteg i samspel

AcuCort
Press release8/19/2025, 11:05 AM

Analyst Group: Analyst Group kommenterar AcuCorts Q2-rapport

AcuCort
Regulatory press release8/19/2025, 6:30 AM

AcuCort AB: AcuCort publicerar delårsrapport för andra kvartalet 2025

AcuCort
Press release8/19/2025, 6:04 AM

Investor Studios: AcuCorts VD Jonas Jönmark presenterar kvartalsrapporten live 11.00

AcuCort
Regulatory press release8/12/2025, 11:54 AM

AcuCort AB: Försäljning av Zeqmelit® har inletts i Danmark

AcuCort
Regulatory press release8/12/2025, 11:54 AM

AcuCort AB: Sales of Zeqmelit® commenced in Denmark

AcuCort
Regulatory press release6/24/2025, 2:32 PM

AcuCort AB: AcuCort offentliggör utfall för nyttjande av teckningsoptioner av serie TO2

AcuCort
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.